FDA Adverse Event Death Summary report: N

OVATION PRIME AORTIC BODY STENT GRAFT SYSTEM

MDR report key: 6358238 · Received February 24, 2017

Report

Report Number
3008011247-2017-00021
Event Type
Death
Date Received
February 24, 2017
Date of Event
November 23, 2016
Report Date
January 25, 2017
Manufacturer
TRIVASCULAR, INC.
Product Code
MIH
UDI-DI
M701TVAB2380D1
PMA / PMN Number
P120006
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CA
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

DEVICE REMAINS IMPLANTED.

Additional Manufacturer Narrative · 1

BASED ON THE CLINICAL ASSESSMENT FOR THIS EVENT, THE MOST LIKELY CAUSE OF THE REPORTED ANEURYSM GROWTH AND INFECT AORTA WAS DETERMINED TO BE UNKNOWN/UNDETERMINED. A CLINICAL ASSESSMENT SHOWED THAT THE DEVICE DID NOT LIKELY CONTRIBUTE TO THIS EVENT. THE LEFT GROIN INFECTION WITHIN 30 DAYS OF THE REPAIR PROCEDURE IS REFLECTIVE OF A PROCEDURE-RELATED HARM. THE NEGATIVE SEQUELAE WAS ALSO EXACERBATED BY THE COMPLEXITY OF THE REPAIR PROCEDURE DUE TO THE PATIENT'S PRE-EXISTING FEMORAL ANATOMY. OFF-LABEL OR CAUTIONARY PRODUCT USE CONDITIONS COULD NOT BE DETERMINED. A REVIEW OF THE DEVICE QUALITY RECORDS SHOWS THAT THE DEVICE DEMONSTRATED COMPLIANCE TO ESTABLISHED PROCEDURES AND SPECIFICATIONS AT THE TIME OF MANUFACTURE. (B)(4).

Description of Event or Problem · 1

AN OVATION PRIME ABDOMINAL STENT GRAFT SYSTEM WAS IMPLANTED TO TREAT AN ABDOMINAL AORTIC ANEURYSM. THE 1 YEAR POST-OPERATIVE CT SHOWED THE PRESENCE OF A POTENTIAL TYPE IA AND/OR TYPE II ENDOLEAK IN THE PRESENCE OF SIGNIFICANT JUXTARENAL ANGULATION AND CALCIUM IN THE SEAL ZONE. AS OF THE DATE OF THIS REPORT, THERE HAVE BEEN NO ADDITIONAL PATIENT SEQUELAE REPORTED AND THE PATIENT WILL CONTINUE TO BE MONITORED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
139204 OVATION PRIME AORTIC BODY STENT GRAFT SYSTEM ENDOVASCULAR GRAFT, ABDOMINAL AORTIC ANEURYSM MIH TRIVASCULAR, INC. TV-AB2380-D FS052115-20 M701TVAB2380D1

Patients

Seq Age Sex Outcome Treatment
1 60 YR Other